Ryan McDonald

Ryan McDonald, Associate Editorial Director for CURE®, has been with the team since February 2020 and has previously covered medical news across several specialties prior to joining MJH Life Sciences. He is a graduate of Temple University, where he studied journalism and minored in political science and history. He considers himself a craft beer snob and would like to open a brewery in the future. During his spare time, he can be found rooting for all major Philadelphia sports teams. Follow Ryan on Twitter @RMcDonald11 or email him at rmcdonald@curetoday.com.

Can a Virtual Reality Program Reduce Chronic Pain From Cancer?

May 10, 2022

Researchers are set to launch a new study to examine the feasibility of using an in-home virtual reality-guided mindfulness program to mitigate the effects of chronic cancer-related pain in patients and cancer survivors.

Patient Receives Treatment With Novel Drug in First-in-Human Trial Assessing its Safety and Efficacy in Brain and Lung Cancer

April 25, 2022

The drug, known as BDTX-1535, is being investigated in patients with glioblastoma that harbors EGFR alterations and non-small cell lung cancer that harbors EGFR mutations of intrinsic or acquired resistance and disease that has failed standard treatment.

Early-Phase Trial to Investigate Novel CAR-T Cell Therapy Alongside Oncolytic Virus in Recurrent Brain Cancer Set to Launch

April 18, 2022

The plan to launch the phase 1 trial to evaluate the safety and efficacy of combining the CAR-T cell therapy and oncolytic virus in patients with recurrent glioblastoma, a type of brain cancer, is supported by interim data from two ongoing trials.

Opdivo-Yervoy Combo Induces Survival Benefit in Advanced Skin Cancer

April 14, 2022

Compared with Yervoy alone, the use of Yervoy plus Opdivo was associated with a significant survival benefit as a second-line treatment in patients with previously treated advanced melanoma, a type of skin cancer.

FDA Approves Yescarta, First CAR-T Cell Therapy, for Patients With Large B-Cell Lymphoma That Has Failed Initial Treatment

April 04, 2022

The FDA’s decision to approve Yescarta in patients with large B-cell lymphoma that has failed to respond to first-line treatment is based on data that showed that the use of the CAR-T cell therapy resulted in a significant increase in patients who were alive at two years compared with the standard-of-care second-line treatment.

Early-Stage Clinical Trial Treats First Patient With Life-Threatening Cancer Metastases With Investigational Drug

March 30, 2022

It is expected that up to 18 patients with leptomeningeal metastases — a serious form of cancer that has spread from its original location to an area surrounding the brain and spinal cord — will receive treatment with the investigational drug.

FDA Rejects Request to Approve Novel Drug Combination in NSCLC

March 27, 2022

The FDA’s decision follows a recommendation from a panel of experts that suggested the agency not approve sintilimab plus the chemotherapy pemetrexed and platinum-based chemotherapy for patients with non-squamous non-small cell lung cancer.

‘Today Show’ Anchor Hoda Kotb Discusses Fertility Issues Following Cancer Diagnosis, Pfizer Pulls Blood Pressure Drugs Due to Cancer Concerns and More

March 25, 2022

From Pfizer issuing a voluntary recall of three blood pressure drugs due to a high level of a cancer-causing chemical to “Today Show” co-ancho Hoda Kotb discussing her struggles with fertility after receiving a diagnosis of breast cancer, here’s what’s happening in the cancer space this week.